You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 398 neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
398 neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC)
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to February 2023

AbstractFullPdf
Nov 2021308018
Dec 202111205
Jan 20228003
Feb 20227508
Mar 2022172014
Apr 202276011
May 202248018
Jun 20223005
Jul 20221404
Aug 20222203
Sep 202224012
Oct 20222007
Nov 202228012
Dec 20222403
Jan 20232203
Feb 20232006
Total10750132